• 1
    Whitaker D, Papadimitriou JM, Walters MN. The mesothelium and its reactions: a review. Crit Rev Toxicol 1982; 10: 81144.
  • 2
    Lanphear BP, Buncher CR. Latent period for malignant mesothelioma of occupational origin. J Occup Med 1992; 34: 71822.
  • 3
    Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin Oncol 2002; 29: 217.
  • 4
    Pass HI, Vogelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer 2004; 28: 93174.
  • 5
    Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999; 79: 66672.
  • 6
    Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591603.
  • 7
    Murayama T, Takahashi K, Natori Y, Kurumatani N. Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. Am J Ind Med 2006; 49: 17.
  • 8
    Curran D, Sahmoud T, Therasse P, Van Meerbeeck J, Postmus PE, Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998; 16: 14552.
  • 9
    Van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 68819.
  • 10
    Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 263644.
  • 11
    Gibas Z, Li FP, Antman KH, Bernal S, Stahel R, Sandberg AA. Chromosome changes in malignant mesothelioma. Cancer Genet Cytogenet 1986; 20: 191201.
  • 12
    Popescu NC, Chahinian AP, DiPaolo JA. Nonrandom chromosome alterations in human malignant mesothelioma. Cancer Res 1988; 48: 1427.
  • 13
    Tiainen M, Tammilehto L, Mattson K, Knuutila S. Nonrandom chromosomal abnormalities in malignant pleural mesothelioma. Cancer Genet Cytogenet 1988; 33: 25174.
  • 14
    Flejter WL, Li FP, Antman KH, Testa JR. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: possible sites of tumor suppressor genes. Genes Chromosomes Cancer 1989; 1: 14854.
  • 15
    Hagemeijer A, Versnel MA, Van Drunen E et al. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet 1990; 47: 128.
  • 16
    Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 1993; 53: 434955.
  • 17
    Lee WC, Balsara B, Liu Z, Jhanwar SC, Testa JR. Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. Cancer Res 1996; 56: 4297301.
  • 18
    Bell DW, Jhanwar SC, Testa JR. Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. Cancer Res 1997; 57: 405762.
  • 19
    Cheng JQ, Jhanwar SC, Klein WM et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994; 54: 554751.
  • 20
    Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995; 11: 51115.
  • 21
    Sekido Y, Pass HI, Bader S et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995; 55: 122731.
  • 22
    Bianchi AB, Mitsunaga SI, Cheng JQ et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci USA 1995; 92: 10854–8.
  • 23
    Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothlioma. J Cell Physiol 1999; 180: 1507.
  • 24
    Jaurand MC, Fleury-Feith J. Pathogenesis of malignant pleural mesothelioma. Respirology 2005; 10: 28.
  • 25
    Metcalf RA, Welsh JA, Bennett WP et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 1992; 52: 261015.
  • 26
    Papp T, Schipper H, Pemsel H et al. Mutational analysis of N-ras, p53, 16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. Int J Oncol 2001; 18: 42533.
  • 27
    Kumar K, Rahman Q, Schipper H, Matschegewski C, Schiffmann D, Papp T. Mutational analysis of 9 different tumour-associated genes in human malignant mesothelioma cell lines. Oncol Rep 2005; 14: 74350.
  • 28
    Usami N, Fukui T, Kondo M et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 2006; 97: 38794.
  • 29
    Kivipensas P, Bjorkqvist AM, Karhu R et al. Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genet Cytogenet 1996; 89: 713.
  • 30
    Bjorkqvist AM, Tammilehto L, Anttila S, Mattson K, Knuutila S. Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. Br J Cancer 1997; 75: 5237.
  • 31
    Bjorkqvist AM, Tammilehto L, Nordling S et al. Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer 1998; 77: 2609.
  • 32
    Balsara BR, Bell DW, Sonoda G et al. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res 1999; 59: 4504.
  • 33
    De Rienzo A, Testa JR. Recent advances in the molecular analysis of human malignant mesothelioma. Clin Ther 2000; 151: 4338.
  • 34
    Krismann M, Müller KM, Jaworska M, Johnen G. Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases. J Pathol 2002; 197: 36371.
  • 35
    Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
  • 36
    Tagawa H, Karnan S, Suzuki R et al. Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 2005; 24: 134858.
  • 37
    Pinkel D, Segraves R, Sudar D et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998; 20: 20711.
  • 38
    Ota A, Tagawa H, Karnan S et al. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004; 64: 308795.
  • 39
    Karnan S, Tsuzuki S, Kiyoi H et al. Genomewide array-based comparative genomic hybridization analysis of acute promyelocytic leukemia. Genes Chromosomes Cancer 2006; 45: 4205.
  • 40
    Tagawa H, Tsuzuki S, Suzuki R et al. Genome-wide array-based comparative genomic hybridization of diffuse large B-cell lymphoma: comparison between CD5-positive and CD5-negative cases. Cancer Res 2004; 64: 594855.
  • 41
    Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30: e36.
  • 42
    Heintz NH, Janssen YM, Mossman BT. Persistent induction of c-fos and c-jun expression by asbestos. Proc Natl Acad Sci USA 1993; 90: 3299303.
  • 43
    Shivapurkar N, Virmani AK, Wistuba II et al. Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. Clin Cancer Res 1999; 5: 1723.
  • 44
    Bjorkqvist AM, Wolf M, Nordling S et al. Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis. Br J Cancer 1999; 81: 11115.
  • 45
    Sandhu H, Dehnen W, Roller M, Abel J, Unfried K. mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. Carcinogenesis 2000; 21: 10239.
  • 46
    Knuuttila A, Jee KJ, Taskinen E, Wolff H, Knuutila S, Anttila S. Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases. Virchows Arch 2006; 448: 13541.
  • 47
    Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1991; 1072: 12957.
  • 48
    Lin DW, Coleman IM, Hawley S et al. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol 2006; 24: 376370.
  • 49
    Klabatsa A, Sheaff MT, Steele JP, Evans MT, Rudd RM, Fennell DA. Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM). Lung Cancer 2006; 51: 539.
  • 50
    Omasa T. Gene amplification and its application in cell and tissue engineering. J Biosci Bioeng 2002; 94: 6005.
  • 51
    Sasaki S, Kitagawa Y, Sekido Y et al. Molecular processes of chromosome 9p21 deletions in human cancers. Oncogene 2003; 22: 37928.
  • 52
    Florl AR, Schulz WA. Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells. Genes Chromosomes Cancer 2003; 23: 1418.
  • 53
    Raschke S, Balz V, Efferth T, Schulz WA, Florl AR. Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines. Genes Chromosomes Cancer 2005; 42: 5867.
  • 54
    Suzuki M, Toyooka S, Shivapurkar N et al. Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogene 2005; 24: 13028.
  • 55
    Shigemitsu K, Sekido Y, Usami N et al. Genetic alteration of the β-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion. Oncogene 2001; 20: 424957.
  • 56
    Usami N, Sekido Y, Maeda O et al. Beta-catenin inhibits cell growth of a malignant mesothelioma cell line, NCI-H28, with a 3p21.3 homozygous deletion. Oncogene 2003; 22: 792330.